Lannett stock has struggled lately due to opioid litigation and a weakening of its earnings forecast back in November. However, the company announced several product launches in December and early January, and today Lannett got FDA approval for, of all things, a cocaine-based anesthetic nasal spray. The stock has shown little positive reaction to any of this news,...
COMMENTARY BIOC is one of those penny stocks that have individual, good days. But when it comes to putting together a string of bullish action, it has yet to reach that milestone. Furthermore, though volume is good, the company still needs to execute further in my opinion. Either way. It's a good day today but would like to put this on a 30 day time clock and...
After-hours today, McKesson raised its FY EPS guidance to 14.60-14.80, about 2% above the consensus analyst estimate of 14.41. Its last round of guidance was disappointing, so this reflects a significant improvement in the company's fundamentals. Even though the guidance bump was only 2%, it could catalyze a much larger move in the stock price, which was already...
If you like this idea, don't forget to hit the Like Button! Alexion business depends on patent-protected therapies in ultrarare and rare diseases of high unmet medical needs. While competitors are entering the market with biosimilars, Alexion still maintains an essential share of the market. My long term view is bullish. However, from a technical point of view,...
Big news from Bayer and Dare today . Next thing to watch is for FDA approval and then if/when commercialization begins. Until then I think it's still very speculative. HOWEVER. important to note the chart. Last time it traded this high, it remained the case for a few weeks and then plummeted back down to earth. The last time it consistently traded around this...
Women's healthcare company - Lots of upcoming catalysts through 2020. New acquisition this week of Microchips. Could see this fall to .50s if earnings are garbage - which is definitely a possibility, but target is still $2-$3 next year. This is speculative, but I will hold 5k shares from .79 avg.
PledPharma OMXSTO:PLED with short term positive momentum on top of recent clinical trial updates. Should be kept on watch list as it could break out from a year long consolidation phase. Recent CEO Interview: www.redeye.se PledPharma to initiate one pivotal Phase II/III study with Aladote® for marketing authorisation application in both US and EU ...
Double bottom Testing resistance for potential breakout.
I've been looking at this company for years, love their proprietary technology. I really think they have huge potential, but as always not financial advise.
I've been adding to my Alexion position since December 9, when I posted my previous idea on this stock. The wait is finally paying off, as the stock has surged higher in the past couple days. Alexion is getting unusually bullish call activity today, and the interest is more than justified at this forward P/E of less than 10 and PEG ratio of less than 1. Alexion...
Good spot for Alexion Pharmaceuticals. The stock is trading above the Ichimoku Cloud Support (red line of the green cloud). I was waiting for today's opening to confirm a bullish position. Furthermore, Alexion trades below its normal Price/Ebitda ratio of 41.13 (currently trading at 11.89). Disclosure: My ideas contain statements and projections based on...
After the stock price touched new highs in October 2019 ( management confirmed rebooting of aducanumab's development), Biogen started a consolidation phase. I plotted the Ichimoku Cloud on a daily chart, together with the Bollinger bands, to highlight the volatility and confirm the consolidation phase. Currently, from a technical point of view, we are in an...
Stochastic Oscillator shows upturn for Acadia. Ichimoku Cloud support is very important in this case since today's session is not breaking it and could demonstrate positive trend force. Please note that biotech companies present high uncertainty. Disclosure: My articles contain statements and projections based on assumptions on capital markets, and therefore...
Great news and all but can SNCA pull from a technical perspective ? "The patent is for the “Transplantation of human neural cells for treatment of neurodegenerative conditions.” Could this be the next step in developing its NSI-566 treatment? Why I say this is because the treatment is specifically designed around neural stem cells. This is developing as things...
Look for biotech stocks to start performing well. Price targets are noted on the chart. Bollinger Band shows a squeeze in this area as well.
Falling wedge in a bigger falling wedge... lets see if it plays out and make us pennies!!
AIM Has a Gap to fill & seen big unsual buying. Has a very Low float. A Biotech stock targeting diffrent cancers, a lot of data due throughout 2020 - Triple-Negative Breast Cancer ; Phase 1 data due 2Q - Colorectal cancer ; Phase 2 date due 2Q - Ovarian cancer ; Phase 1 interim data due 1Q - Ovarian cancer ; Phase 2 data due 4Q
On the watchlist VBI-1501 Phase 2 trial to start 1H 2020 Sci-B-Vac - CONSTANT Phase 3 data due early january BRII-179 (VBI-2601) Phase 2 data due 2H 2020